Y-mAbs up on EMA's nod to pediatric investigation plan for cancer drug

Y-mAbs Therapeutics

02/02/2023 19:36

** Shares of drugmaker Y-mAbs Therapeutics Inc  YMAB.O  rise
1.51% to $4.71
    ** Co says the European Medicines Agency (EMA) has agreed to
the proposed pediatric investigation plan for nerve cell cancer
drug, naxitamab
    ** The decision follows a positive opinion from EMA's
Pediatric Committee
    ** The drug is being developed for the treatment of patients
with a type neuroblastoma, a cancer that develops from immature
nerve cells found in several areas of the body
    ** A pediatric investigation plan is a development plan
aimed at ensuring that the necessary data are obtained through
studies in children, to support the authorization of a medicine
for children
    ** Co's stock lost 70% in 2022
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))